

DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE  
CENTERS FOR DISEASE CONTROL

MINUTES OF MEETING

Immunization Practices Advisory Committee  
January 31-February 1, 1985  
Atlanta, Georgia

The Immunization Practices Advisory Committee (ACIP) met in Room 207 at the Centers for Disease Control, Atlanta, Georgia, on January 31-February 1, 1985. Those in attendance are listed below:

COMMITTEE MEMBERS PRESENT

Dr. James Chin, Chairman  
Dr. Ellen S. Alkon  
Dr. David S. Fedson  
Dr. Anne A. Gershon  
Dr. Donald A. Henderson  
Dr. Samuel L. Katz  
Dr. Joan K. Leavitt  
Dr. Edward A. Mortimer  
Dr. William Schaffner II

Ex Officio Members

Dr. William S. Jordan, Jr. (NIH)  
Dr. Harry Meyer, Jr. (FDA)  
(represented by Dr. Elaine Esber)

Liaison Representatives

Dr. Philip A. Brunell (AAP)  
Dr. Jarrett Clinton (DD)  
Dr. J. M. S. Dixon (NACI)  
Dr. Theodore C. Eickhoff (ACP)  
Dr. Albert W. Pruitt (AMA)

Executive Secretary

Dr. Jeffrey P. Koplan

COMMITTEE MEMBERS ABSENT

Mrs. Betty F. Bumpers

HHS STAFF PRESENT

FOOD AND DRUG ADMINISTRATION

Center for Drugs and Biologics

Dr. Elaine Esber  
Dr. Bruce Burlington  
Dr. Carolyn Hardegree  
Dr. Gerald Quinnan, Jr.

CENTERS FOR DISEASE CONTROL

Office of the Director

Dr. Donald R. Hopkins  
Mr. John E. Jaugstetler  
Ms. Verla Neslund  
Ms. Gwendolyn Strickland-Cid

Center for Infectious Diseases

Dr. Miriam Alter  
Dr. John Bennett  
Dr. Claire V. Broome  
Dr. Steven L. Cochi  
Dr. Mitchell Cohen  
Dr. Martin Favero  
Dr. Stephen Hadler  
Dr. Mark A. Kane  
Dr. Alan P. Kendal  
Dr. Ludwig A. Lettau  
Dr. Harold Margolis  
Dr. James Maynard  
Dr. Fred A. Murphy  
Dr. Margaret Oxtoby  
Dr. Arthur Reingold  
Dr. Frederic Shaw

Center for Prevention Services

Dr. Kenneth J. Bart  
Mr. Windell R. Bradford  
Dr. Edward W. Brink  
Dr. Ronald Davis  
Dr. Alan H. Hinman  
Mr. Philip R. Horne  
Dr. Ida M. Onorato  
Dr. Walter Orenstein  
Dr. Stephen Preblud  
Dr. Harrison Stetler  
Dr. Steven Wassilak

International Health Program Office

Dr. T. Stephen Jones  
Dr. Kenneth Bernard

OTHERS PRESENT

Dr. Bill Burns  
Mr. Robert Byrd  
Colonel Alfred K. Cheng (USAF)  
Dr. Benedict Diniega  
Dr. H. Bruce Dull  
Dr. Constance A. Finch  
Dr. Alan H. Goldschein  
Dr. Lance Gordon  
Dr. Alan Gray  
Dr. Harry Guess  
Dr. Jill G. Hackell  
Dr. Victor Jegede  
Dr. Ruth J. Katz  
Dr. Saul Krugman  
Dr. Eva Lydick  
Dr. Donald W. McCoy

Dr. Cristina Michiewicz  
Dr. Mark Perrin  
Dr. Stanley A. Plotkin  
Dr. George Politis  
LCDR H. G. Potter, MC USN  
Dr. Benjamin A. Rubin  
Col. Robert G. Self, USAF, MC  
Dr. Jane V. Scott  
Ms. Karlyn L. Shedlowski  
Dr. David H. Smith  
Ms. Marjorie Sun  
Dr. Ralph A. Vosdingh  
Mr. Tim Westmoreland  
Dr. Richard F. White  
Dr. Paul Wilson  
Dr. Barbara A. Zajac

The meeting was opened at 8:30 a.m. on January 31 by Dr. James Chin, Chairman. Dr. Chin welcomed members of the Committee and others present and introduced Donald R. Hopkins, M.D., recently appointed Deputy Director of the Centers for Disease Control (CDC).

Hepatitis B

Dr. James Maynard and staff from the Division of Viral Diseases (DVD), Center for Infectious Diseases (CID), CDC, discussed low seroconversion rates in hepatitis B vaccine recipients. Dr. Stephen C. Hadler, DVD, CID, CDC, and Dr. Harry Guess, Merck, Sharpe, and Dohme Research Laboratories, presented data indicating that response to vaccination in gluteal region (75-82%) is significantly poorer than response to vaccination in the deltoid muscle (>90%). Dr. Chin suggested and the Committee agreed that an article be prepared for publication in the MMWR. Dr. Hadler will prepare the article.

Dr. Hadler presented for review and discussion an updated draft of "Recommendations on Immune Globulins for Pre- and Post-Exposure Protection Against Viral Hepatitis." The draft incorporates the recommendation "Postexposure Prophylaxis of Hepatitis B," placing all relevant ACIP recommendations on immune globulins in one statement. Specific points discussed were recommendations for immunoglobulins for travelers, prophylaxis of needlestick accidents in persons already vaccinated for hepatitis B, and reasons for suboptimal response to hepatitis B virus (HBV) in some hospitals. Dr. Hadler will redraft the statement to include the Committee's suggestions. The draft will be recirculated to the Committee for their review and written comments so that the final draft can be presented at the April meeting.



### Varicella Zoster Status

Dr. Alan Hinman, Division of Immunization (DI), Center for Prevention Services (CPS), CDC, gave introductory comments on the status of varicella zoster vaccine and introduced a panel: Dr. Stephen Preblud, DI, CPS, discussed a benefit-cost analysis of the vaccine. Dr. Anne Gershon, Committee member, presented data from an NIAID collaborative vaccine study in children with underlying immunodeficiency. Dr. Stanley A. Plotkin, Professor of Pediatrics at Children's Hospital of Philadelphia, and Dr. Philip Brunell, liaison representative from the American Academy of Pediatrics, discussed their data. Dr. Barbara A. Zajack from Merck Sharp and Dohme (MSD) gave an overview of MSD intentions regarding the vaccine. Dr. Gerald V. Quinnan, Jr., FDA, discussed safety, efficacy, combination with MMR, and licensure status of the vaccine.

### Poliomyelitis

Dr. Ida Onorato, DI, CPS, CDC, who had recently returned from Finland, summarized a polio outbreak in Finland. As of January 9, 1985, four cases of paralytic and one case of nonparalytic poliomyelitis had been diagnosed and confirmed during the previous 2 months from various parts of Finland.

### DTP and Compensation Issues

Prior to the ACIP meeting, members had received and submitted comments on a revised draft of "Diphtheria, Tetanus, and Pertussis: Guidelines for Vaccine Prophylaxis and Other Preventive Measures" scheduled for updating. After a discussion led by Dr. Alan Hinman, Dr. Chin asked the Committee to send any additional comments to Dr. Koplan within 2 weeks. A revision will be made from the comments and recirculated.

Dr. Hinman presented facts regarding the vaccine compensation-liability issues. Lederle has been purchasing DTP vaccine stock from Wyeth Laboratories, since Wyeth ceased production of the vaccine. The vaccine shortage will be tight for another month or so. The Division of Immunization, CPS, is surveying State health departments to determine the supply. Vaccine Injury Compensation Bills have been presented in both the House and Senate. The AMA Ad Hoc Commission on Vaccine Injury Compensation will sponsor a Bill in the next Session. The Institute of Medicine is looking into the vaccine compensation-liability problem. The Committee agreed that a strategy is needed for coping with the vaccine shortage if Lederle should cease production.

### Haemophilus Influenzae

Dr. Claire V. Broome and staff led a discussion of a draft recommendation, "Haemophilus influenza Type b Polysaccharide Vaccine," which had been mailed to the Committee for their review prior to the meeting. The purposes of the statement are to summarize available information about the vaccine and to offer guidelines for its use in the prevention of invasive H. influenzae type b (Hib) disease when a polysaccharide vaccine is licensed in the United States. It was noted that "Haemophilus b Vaccine" is the official name. Dr. Chin thanked the sub-committee (Drs. Katz, Leavitt, and Mortimer) and Dr. Broome's staff for formulating the draft recommendation. Data were presented on recommendations for use of vaccine at 18 months versus 24 months of age and use of Hib vaccine in children above 24 months.



Dr. David H. Smith, Praxis Biologics, presented data on Hib vaccine.

Dr. Chin asked Dr. Broome to incorporate into the statement the Committee's suggested changes and present the draft for review and comments the following day.

#### Day Two:

On Friday, February 1, Dr. Stephen L. Cochi reviewed the changes made in the draft and asked for comments. After discussion of changes, Dr. Chin asked the sub-committee to incorporate the Committee's suggestions and recirculate the draft to the Committee for their review and final comments.

#### Meningococcal Polysaccharide Vaccines

Dr. Arthur Reingold, Division of Bacterial Diseases (BD), CID, CDC, led a discussion of an updated draft, "Meningococcal Vaccines," which had been mailed to the Committee for their review prior to the meeting. Polysaccharide vaccines against disease caused by Neisseria meningitis serogroups A,C,Y and W-135 are licensed in the United States. The revision summarizes available information on the vaccines and offers guidelines for their use in the civilian population of the United States. Points discussed were potential target groups for vaccination, preventive measures for contacts of sporadic cases, revaccination of whom and when, and cost of vaccines in the United States.

A slide presentation by Dr. Margaret Oxtoby, BD, CID, discussed data on vaccine efficacy studies in U.S. Army recruits and Egyptian school children, and studies of the duration of vaccine-induced clinical protection in Burkina Faso. Dr. Chin stated that any additional comments should be mailed or called in soon so that the changes can be incorporated in the draft and mailed to the Committee for their review.

#### Vaccinia

Dr. T. Steven Jones, Office of International Health, CDC, presented a revision of the current recommendation "Smallpox Vaccine" for the Committee's review and comments. The update includes information on changes in the International Health Regulations and in distribution of the vaccine to civilians. Dr. Jones stressed that smallpox vaccine is indicated only for civilian laboratory workers directly involved with smallpox (variola virus) or other closely related orthopox viruses. In January 1982, requirement for smallpox vaccination for international travel was deleted from the International Health Regulations. After discussion, Dr. Jones asked the Committee to send in additional comments to be incorporated in the draft within 2 or 3 weeks.

#### Influenza

Dr. Alan Kendal, Division of Viral Diseases (VD), CID, distributed selected revised portions of the May 1984 recommendation on Prevention and Control of Influenza.

As background for general discussion, Dr. Peter A. Patriarca, VD, CID, presented data on hemagglutination-inhibition reactions and international influenza virus surveillance on types A(H1N1), A(H3N2), and B influenza for the 1984-1985 season. From April through December 1984, worldwide influenza activity has been relatively low. Influenza viruses were associated with some regional outbreaks, and virus isolates were most often from sporadic cases or those associated with focal outbreaks. An increase in type A(H3N2) activity in the United States has not been observed in other parts of the world. Also, discussed was the efficacy of inactivated influenza A and B vaccines in reducing influenza-like illness in nursing homes from 1975-1984.

After discussion, the Committee agreed to include in the statement information on: route of vaccine administration, use of amantadine in medical personnel during influenza A outbreaks, contingency plans to expedite use of amantadine in aborting influenza A outbreaks among residents of institutions, and reduction in the daily dosage of amantadine for elderly patients without recognized renal disease. Dr. Kendal will modify the draft and circulate it to Committee members for their review and comments.

#### Other ACIP Business

The next Committee meeting was scheduled for April 15-16, 1985. Tentative agenda items will include Reye's Syndrome update, influenza update, hepatitis B status, vaccine use during pregnancy and in the immunocompromised, and rabies vaccine update. Dr. Koplan asked members to submit to him other items they wished placed on the agenda.

With the thanks of the Chairman, the meeting was adjourned at 1 p.m.

I hereby certify that, to the best of my knowledge, the foregoing summary of minutes is accurate and complete.

James Chin 3/4/85  
James Chin, M.D., Chairman Date